title: Risk for fracture in women with low serum levels of thyroid-stimulating hormone.
abstract: BACKGROUND
  Biochemical evidence of hyperthyroidism may be associated with low bone mass, particularly in older postmenopausal women, but no prospective studies of thyroid function and subsequent fracture risk have been done.
  
  
  OBJECTIVE
  To examine the association between low levels of thyroid-stimulating hormone (TSH) and fracture in older women.
  
  
  METHODS
  Prospective cohort study with case-cohort sampling.
  
  
  METHODS
  Four clinical centers in the United States.
  
  
  METHODS
  686 women older than 65 years of age from a cohort of 9704 women recruited from population-based listings between 1986 and 1988.
  
  
  METHODS
  Baseline assessment of calcaneal bone mass, spine radiography, and history of thyroid disease. Spine radiography was repeated after a mean follow-up of 3.7 years; nonspine fractures were centrally adjudicated. Thyroid-stimulating hormone was measured in sera obtained at baseline from 148 women with new hip fractures, 149 women with new vertebral fractures, and a subsample of 398 women randomly selected from the cohort.
  
  
  RESULTS
  After adjustment for age, history of previous hyperthyroidism, self-rated health, and use of estrogen and thyroid hormone, women with a low TSH level (0.1 mU/L) had a threefold increased risk for hip fracture (relative hazard, 3.6 [95% CI, 1.0 to 12.9]) and a fourfold increased risk for vertebral fracture (odds ratio, 4.5 [CI, 1.3 to 15.6]) compared with women who had normal TSH levels (0.5 to 5.5 mU/L). After adjustment for TSH level, a history of hyperthyroidism was associated with a twofold increase in hip fracture (relative hazard, 2.2 [CI, 1.0 to 4.4]), but use of thyroid hormone itself was not associated with increased risk for hip fracture (relative hazard, 0.5 [CI, 0.2 to 1.3]).
  
  
  CONCLUSIONS
  Women older than 65 years of age who have low serum TSH levels, indicating physiologic hyperthyroidism, are at increased risk for new hip and vertebral fractures. Use of thyroid hormone itself does not increase risk for fracture if TSH levels are normal.
authors.affiliation: University of California, San Francisco, 74 New Montgomery, Suite 600, San Francisco, CA 94105, USA.
authors.forename: D C
authors.initials: DC
authors.lastname: Bauer
authors.forename: B
authors.initials: B
authors.lastname: Ettinger
authors.forename: M C
authors.initials: MC
authors.lastname: Nevitt
authors.forename: K L
authors.initials: KL
authors.lastname: Stone
mesh_terms: D000368:Aged; D015519:Bone Density; D016022:Case-Control Studies; D015914:Estrogen Replacement Therapy; D005500:Follow-Up Studies; D050723:Fractures, Bone / Q000209:etiology; D006620:Hip Fractures / Q000209:etiology*; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood / Q000150:complications; D008297:Male; D017698:Postmenopause / Q000097:blood*; D011446:Prospective Studies; D012307:Risk Factors; D016103:Spinal Fractures / Q000209:etiology*; D013963:Thyroid Hormones / Q000627:therapeutic use; D013972:Thyrotropin / Q000097:blood*
chemical_list: D013963:Thyroid Hormones; D013972:Thyrotropin